Intelligent Bio Solutions completed its initial clinical Cut-off Study for a fingerprint-based codeine screen in 40 adults, finalizing data on schedule and aligning test performance against an FDA-cleared predicate with LC-MS/MS confirmation. The readout supports the company’s planned 510(k) submission for U.S. clearance of its instrumented DSR-Plus reader and disposable cartridge system.
The company is moving immediately into a multi-site Method Comparison and Usability Study operated by intended end users, targeting completion by the end of June 2026, alongside an Interference Study to evaluate performance in the presence of real-world substances, expected by late July. The stepwise program is designed to demonstrate substantial equivalence to an existing device while building an evidence package around usability and matrix-specific risks for fingerprint sweat.
Strategically, this is a targeted entry into a crowded drugs-of-abuse testing market using a differentiated specimen type. By leading with a single analyte—codeine—on a reader-based platform, the company is aiming for the most straightforward regulatory path available for a novel matrix. Anchoring the dossier with predicate comparisons and confirmatory LC-MS/MS is table stakes; the added emphasis on interference and operator usability testing signals sensitivity to FDA’s scrutiny of point-of-collection devices used outside traditional labs. The bigger question is classification: if FDA determines that fingerprint sweat lacks a suitable predicate for the claimed intended use, the pathway could shift from 510(k) to de novo, altering timelines and evidence expectations. Positioning around “recent use” rather than impairment will also matter, as impairment claims typically invite higher evidentiary bars and cross-agency complexities.
If cleared, the operational pitch is clear: hygienic, observed, rapid collection without restroom logistics, and lower adulteration risk relative to urine. That is attractive for nonregulated workplace screening and potentially for pain management or treatment programs that want an immediate screen before definitive confirmation. For research sites and CROs, a portable, instrument-read screen could streamline pre-visit checks, reduce protocol deviations tied to prohibited substance use, and fit into decentralized or community-based settings where sample handling is a constraint. However, chain-of-custody requirements, confirmation workflows, and site SOP integration will determine real uptake. Federal workplace programs governed by SAMHSA/DOT remain aligned to urine (and, increasingly, oral fluid) with certified-lab confirmation; fingerprint sweat is not in that framework today, limiting penetration into regulated segments in the near term.
Vendors in oral fluid and cup-based urine categories should view the move as a potential wedge toward broader multiplex fingerprint panels if the first 510(k) lands. Reader-based fluorescence can deliver more controlled cut-off adherence and digital result capture, which aligns with employers and sponsors pushing for auditable, data-forward screening tools. That said, the absence of published sensitivity/specificity and agreement metrics leaves performance positioning untested against high-quality oral fluid assays and next-gen lateral flow systems.
Next milestones to watch are the method comparison outputs, interference panel composition and results, and—critically—the intended use language in the 510(k) that clarifies target settings and claims. Any signal that FDA requests de novo classification, additional clinical data across diverse populations, or labeling constraints around “recent use” would recalibrate timelines and market scope. Equally important will be whether the company moves quickly to add analytes and multiplexing, and whether it pursues CLIA-related strategies for clinical environments even if the initial adoption skews to nonclinical employers. The near-term opportunity is operational convenience; the constraint is regulatory fit for a new matrix in a policy space that is evolving but still conservative about what constitutes acceptable evidence and use.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
